GD2 CAR-iNeuts

GD2 CAR-iNeuts are an experimental cell therapy consisting of neutrophils derived from induced pluripotent stem cells (iPSCs) and engineered to express a chimeric antigen receptor (CAR) targeting the disialganglioside (GD2) antigen. Developed by researchers at the University of Wisconsin-Madison and the Morgridge Institute for Research, these 'iNeuts' are generated using ETV2 modified mRNA and a 3rd generation CAR construct (14g2A-CD28-OX40-CD3z) integrated into the AAVS1 locus via CRISPR/Cas9. Unlike traditional CAR-T or CAR-NK therapies, neutrophils possess a natural ability to traffic efficiently into the immunosuppressive microenvironment of solid tumors. Preclinical studies demonstrate that GD2 CAR-iNeuts exhibit potent, antigen-specific cytotoxicity against GD2-expressing neuroblastoma and melanoma cells, producing high levels of pro-inflammatory cytokines such as IFN-gamma and TNF-alpha upon tumor stimulation. In vivo models have shown that serial infusions of these cells can significantly reduce tumor burden and increase survival without observed toxicity.

Other names

anti-GD2 CAR neutrophilsanti-GD-2 CAR neutrophilsanti-GD 2 CAR neutrophilsGD2-targeted iPSC-derived neutrophilsGD-2-targeted iPSC-derived neutrophilsGD 2-targeted iPSC-derived neutrophils